CATEGORIES
- HGH & Peptide
- Testosterone Series
- Nandrolone Series
- Boldenon Series
- Trenbolone Series
- DHEA Series
- Oral Steroids Series
- Antiestrogen Series
- Estrogen series
- Epinephrine & Thyroxine
- Nootropic API
- SARMs
- Finished Steroid
- Molecularly targeted cancer API
Latest news
- The dosage of HGH
- The History of HGH
- What is HGH?
- High Growth hormone
- How to use HGH?
- The Copy of Growth Hormone
Contact us
- ADD: HongKong
- TEL: skype: sophia.koffeepharm
- FAX: sophia@koffeepharm.com
- E-mail: sophia@koffeepharm.com
TOFACITINIB CITRATE
- Product description: supply good quality TOFACITINIB CITRATE CAS:540737-29-9
PRODUCT INTRODUCTION
TOFACITINIB CITRATE
Detailed Product Description
|
Product Name: |
Tofacitinib Citrate |
Purity: |
99%min |
Packaging: |
Safety And Discreet PKG |
Delivery: |
Special Disguised Package Or Customized Guarantee 100% Custom Pass Rate |
|
Courier: |
EMS, HKEMS, FedEx, TNT, DHL |
Payment: |
MoneyGram, Western Union, T/T, |
|
COA Result: |
Available |
Fuction: |
MALE SEX ENHANCER |
|
MOQ: |
10g |
User: |
Adult |
JAK Pathway Inhibitors Powder Tofacitinib Citrate Treating Rheumatoid Arthritis CAS No.540737-29-9
Just try a small order to start our cooperation, we will NOT make you down !
Any products interested pls let me know I will give info.in details.
CAS No.540737-29-9
Chemical Name:Tofacitinib citrate
SynonymsXeljanz;CP 690500-10;CP 690550-10;Tofacitinib API;CP-690550 citrate;Tasocitinib citrate;Tofacitinib citrate;Tofacitinib Citratet;Tofacititinib cirate;Xeljanz(tofacitinib)
CBNumber:CB92460269
Molecular Formula:C16H20N6O.C6H8O7
Formula Weight:504.497
storage temp. room temp
solubility DMSO: soluble5mg/mL (clear solution; warmed)
color white to beige
Description
Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine). Xeljanz is approved by the daily dose of 2 times, each time 5mg.
Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical
function.
In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.
Using Xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Xeljanz product label attaches boxed warning on these security risks. Xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.
In order to study Xeljanz long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Xeljanz (Tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control.